Related Experiment Video
Updated: May 31, 2026

From a Natural Product to Its Biosynthetic Gene Cluster: A Demonstration Using Polyketomycin from Streptomyces diastatochromogenes Tü6028
Published on: January 13, 2017
Aggregicyclins Shed Light on Type II Polyketide Biosynthesis in Myxococcota
Chantal D Bader1,2, Sophia Panter1, Fabian Panter1
1Department of Microbial Natural Products, Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI) and Department of Pharmacy, Saarland University, Campus E8 1, Saarbrücken 66123, Germany.
None:
Polycyclic bacterial specialized metabolites such as anthraquinones, angucyclines, and tetracyclines are predominantly produced by type II polyketide synthase (PKS) systems and represent an important source of antibiotics and anticancer agents. While type II PKS pathways are well characterized in Gram-positive bacteria, their biosynthetic potential in Gram-negative bacteria remains largely unexplored. Here, we report the discovery and activation of a cryptic type II PKS biosynthetic gene cluster from the myxobacterium Aggregicoccus edonensis MCy10622. Using a rapid PCR-based cloning and promoter-exchange strategy, the compact gene cluster was heterologously expressed in Myxococcus xanthus DK1622, leading to the production of two previously unknown specialized metabolites, aggregicyclin and oxyaggregicyclin. Structural analysis revealed an unusual polycyclic scaffold featuring a wide-spanning biaryl ether linkage. Biosynthetic analysis supports an early diversification event during first-ring cyclization as the basis for product divergence. Aggregicyclin exhibits antibacterial activity against Staphylococcus aureus and cytotoxicity against human cancer cells. Together, these findings expand the current knowledge of type II polyketide biosynthesis in Gram-negative bacteria.
More Related Videos
11:45Fluorescence Live-cell Imaging of the Complete Vegetative Cell Cycle of the Slow-growing Social Bacterium Myxococcus xanthus
Published on: June 20, 2018
10:41The Logic, Experimental Steps, and Potential of Heterologous Natural Product Biosynthesis Featuring the Complex Antibiotic Erythromycin A Produced Through E. coli
Published on: January 13, 2013
Related Concept Videos
Bacterial Phylum Actinobacteria
Inhibitors of Gram-positive Cell Wall Synthesis
Peptidoglycan Synthesis
Inhibitors of Bacterial Protein Synthesis
Biosynthesis in Bacteria
Production of Antibiotics